학술논문
Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
Document Type
article
Author
Eke, Ahizechukwu C; Wang, Jiajia; Amin, Khadija; Shapiro, David E; Stek, Alice; Smith, Elizabeth; Chakhtoura, Nahida; Basar, Michael; George, Kathleen; Knapp, Katherine M; João, Esaú C; Rungruengthanakit, Kittipong; Capparelli, Edmund; Burchett, Sandra; Mirochnick, Mark; Best, Brookie M; Bettica, Linda; Calilap-Bernardo, Charmane; Bardeguez, Arlene; Buschur, Shelley; Jackson, Chivon; Paul, Mary; La Russa, Philip; Florez, Claudia; Bryan, Patricia; Stone, Monica; McLaud, Debra; Yarrington, Christina; Clarke, Diana; Deygoo, Nagamah; Borkowsky, William; Kamer, Françoise; Spencer, LaShonda; Homans, James; Joao, Esau C; Braga, Camille Medeiros; Losso, Marcelo H; Ivalo, Silvina A; Hakim, Alejandro; Schmidt, Julie; McNichols, Maureen; Aziz, Mariam; Deville, Jaime G; Nielsen, Karin; Ank, Bonnie; Sublette, Nina; Thorpe, Edwin
Source
Antimicrobial Agents and Chemotherapy. 64(4)
Subject
Language
Abstract
The purpose of this study was to evaluate the pharmacokinetics of ritonavir-boosted fosamprenavir during pregnancy and postpartum. Amprenavir (the active moiety of fosamprenavir) and ritonavir intensive pharmacokinetic evaluations were performed at steady state during the second and third trimesters of pregnancy and postpartum. Plasma concentrations of amprenavir and ritonavir were measured using high-performance liquid chromatography. The target amprenavir area under the concentration-versus-time curve (AUC) was higher than the 10th percentile (27.7 μg · h/ml) of the median area under the curve for ritonavir-boosted fosamprenavir in adults receiving twice-daily fosamprenavir-ritonavir at 700 mg/100 mg. Twenty-nine women were included in the analysis. The amprenavir AUC from time zero to 12 h (AUC0-12) was lower (geometric mean ratio [GMR], 0.60 [confidence interval {CI}, 0.49 to 0.72] [P